Description: Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.
Home Page: regeneus.com.au
16 Goodhope Street
Paddington,
NSW
2021
Australia
Phone:
61 1300 995 098
Officers
| Name | Title |
|---|---|
| Mr. Karolis Rosickas | Chief Executive Officer |
| Prof. Graham Vesey Ph.D. | Chief Scientific Officer & Executive Director |
| Dr. Charlotte Morgan Ph.D. | Head of Research & Development |
| Ling Leung Hang | Company Secretary |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6859 |
| Price-to-Sales TTM: | 3625.7467 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |